Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.

Stevens AM, Xiang M, Heppler LN, Tošić I, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, Seashore EL, Terrell MC, Rashid R, Krueger MJ, Mangubat-Medina AE, Ball ZT, Sumazin P, Walker SR, Hamada Y, Oyadomari S, Redell MS, Frank DA.

Blood Adv. 2019 Dec 23;3(24):4215-4227. doi: 10.1182/bloodadvances.2019000499.

2.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.

Allegretti PA, Horton TM, Abdolazimi Y, Moeller HP, Yeh B, Caffet M, Michel G, Smith M, Annes JP.

Bioorg Med Chem. 2020 Jan 1;28(1):115193. doi: 10.1016/j.bmc.2019.115193. Epub 2019 Nov 11.

PMID:
31757680
3.

Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.

Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML.

J Clin Invest. 2020 Jan 13. pii: 130189. doi: 10.1172/JCI130189. [Epub ahead of print]

4.

Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.

Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP.

Br J Haematol. 2019 Jul;186(2):274-285. doi: 10.1111/bjh.15919. Epub 2019 Apr 7.

PMID:
30957229
5.

Structure of the IFNγ receptor complex guides design of biased agonists.

Mendoza JL, Escalante NK, Jude KM, Sotolongo Bellon J, Su L, Horton TM, Tsutsumi N, Berardinelli SJ, Haltiwanger RS, Piehler J, Engleman EG, Garcia KC.

Nature. 2019 Mar;567(7746):56-60. doi: 10.1038/s41586-019-0988-7. Epub 2019 Feb 27.

6.

Zinc-Chelating Small Molecules Preferentially Accumulate and Function within Pancreatic β Cells.

Horton TM, Allegretti PA, Lee S, Moeller HP, Smith M, Annes JP.

Cell Chem Biol. 2019 Feb 21;26(2):213-222.e6. doi: 10.1016/j.chembiol.2018.10.019. Epub 2018 Dec 6.

PMID:
30527998
7.

Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors.

Gale TV, Horton TM, Hoffmann AR, Branco LM, Garry RF.

J Proteome Res. 2019 Jan 4;18(1):7-17. doi: 10.1021/acs.jproteome.8b00204. Epub 2018 Nov 5.

PMID:
30351952
8.

Transmissible ER stress reconfigures the AML bone marrow compartment.

Doron B, Abdelhamed S, Butler JT, Hashmi SK, Horton TM, Kurre P.

Leukemia. 2019 Apr;33(4):918-930. doi: 10.1038/s41375-018-0254-2. Epub 2018 Sep 11.

9.

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM.

Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16.

10.

Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic.

Hoff FW, Hu CW, Qutub AA, de Bont ESJM, Horton TM, Kornblau SM.

Expert Rev Proteomics. 2018 Jul;15(7):613-622. doi: 10.1080/14789450.2018.1487781. Epub 2018 Jul 6. Review.

11.

Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance.

Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Scheurer ME, de Bont ESJM, Qutub AA, Kornblau SM, Horton TM.

Mol Cancer Res. 2018 Aug;16(8):1263-1274. doi: 10.1158/1541-7786.MCR-17-0730. Epub 2018 Apr 18.

12.

Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets.

Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, de Bont ESJM, Qutub AA, Horton TM, Kornblau SM.

Mol Cancer Res. 2018 Aug;16(8):1275-1286. doi: 10.1158/1541-7786.MCR-17-0731. Epub 2018 Apr 18.

13.

CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.

Abdolazimi Y, Zhao Z, Lee S, Xu H, Allegretti P, Horton TM, Yeh B, Moeller HP, Nichols RJ, McCutcheon D, Shalizi A, Smith M, Armstrong NA, Annes JP.

Endocrinology. 2018 Sep 1;159(9):3143-3157. doi: 10.1210/en.2018-00083.

14.

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT.

Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.

15.

Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.

Gale TV, Horton TM, Grant DS, Garry RF.

PLoS Negl Trop Dis. 2017 Sep 18;11(9):e0005943. doi: 10.1371/journal.pntd.0005943. eCollection 2017 Sep.

16.

Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

Haematologica. 2017 Sep;102(9):e340-e343. doi: 10.3324/haematol.2017.168815. Epub 2017 Jun 22. No abstract available.

17.

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.

Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML.

Leukemia. 2017 Dec;31(12):2568-2576. doi: 10.1038/leu.2017.136. Epub 2017 May 9.

18.

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.

Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K.

J Clin Pharmacol. 2017 Sep;57(9):1183-1193. doi: 10.1002/jcph.906. Epub 2017 Apr 18.

19.

The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.

Mendoza JL, Schneider WM, Hoffmann HH, Vercauteren K, Jude KM, Xiong A, Moraga I, Horton TM, Glenn JS, de Jong YP, Rice CM, Garcia KC.

Immunity. 2017 Mar 21;46(3):379-392. doi: 10.1016/j.immuni.2017.02.017.

20.

Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia.

Gramatges MM, Deshpande A, Lupo PJ, Rau RE, Redell ML, Horton TM, Scheurer ME, Rabin KR.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26487. Epub 2017 Mar 7.

PMID:
28266784
21.

IDENTIFYING CANCER SPECIFIC METABOLIC SIGNATURES USING CONSTRAINT-BASED MODELS.

Schultz A, Mehta S, Hu CW, Hoff FW, Horton TM, Kornblau SM, Qutub AA.

Pac Symp Biocomput. 2017;22:485-496. doi: 10.1142/9789813207813_0045.

22.

Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.

Shen Y, Park CS, Suppipat K, Mistretta TA, Puppi M, Horton TM, Rabin K, Gray NS, Meijerink JPP, Lacorazza HD.

Leukemia. 2017 Jun;31(6):1314-1324. doi: 10.1038/leu.2016.339. Epub 2016 Nov 22.

PMID:
27872496
23.

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.

Niewerth D, Kaspers GJ, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, Alonzo TA, van de Ven PM, Horton TM, Cloos J.

J Hematol Oncol. 2016 Sep 6;9(1):82. doi: 10.1186/s13045-016-0312-z.

24.

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.

Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, Chng WJ, Horton TM, Menezes RX, Musters RJ, Zweegman S, Jansen G, Cloos J.

Oncotarget. 2016 Nov 15;7(46):74779-74796. doi: 10.18632/oncotarget.11340.

25.

Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.

Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

J Clin Oncol. 2016 May 1;34(13):1537-43. doi: 10.1200/JCO.2015.65.5860. Epub 2016 Feb 16.

26.

A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.

Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R.

Leuk Lymphoma. 2016 Jul;57(7):1567-74. doi: 10.3109/10428194.2015.1088652. Epub 2016 Jan 4.

27.

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.

Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL.

Br J Haematol. 2015 Jul;170(1):118-22. doi: 10.1111/bjh.13388. Epub 2015 Apr 1.

28.

Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding.

Visperas PR, Winger JA, Horton TM, Shah NH, Aum DJ, Tao A, Barros T, Yan Q, Wilson CG, Arkin MR, Weiss A, Kuriyan J.

Biochem J. 2015 Jan 1;465(1):149-61. doi: 10.1042/BJ20140793.

29.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA.

Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. doi: 10.1002/pbc.25117. Epub 2014 Jun 29.

30.

AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.

Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI.

Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25.

31.

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.

Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J.

Haematologica. 2013 Dec;98(12):1896-904. doi: 10.3324/haematol.2013.092411. Epub 2013 Sep 20.

32.

Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee.

Levy AS, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM.

J Pediatr Hematol Oncol. 2013 Aug;35(6):456-61. doi: 10.1097/MPH.0b013e31829eec33.

33.

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2013 Mar;60(3):390-5. doi: 10.1002/pbc.24271. Epub 2012 Aug 9.

34.

Analysis of NF-κB Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome-A Children's Oncology Group Study.

Horton TM, Sheehan AM, López-Terrada D, Hutchison RE, Narendra S, Wu MF, Liu H.

Lymphoma. 2012;2012. pii: 341629. doi: 10.1155/2012/341629.

35.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM.

Clin Cancer Res. 2011 Nov 15;17(22):7058-66. doi: 10.1158/1078-0432.CCR-11-1873. Epub 2011 Sep 9. Erratum in: Clin Cancer Res. 2012 Feb 1;18(3):913. Dosage error in article text.

36.

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.

Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, Greenberger LM, Horak ID, Grupp SA, Teachey DT, Raetz EA, Carroll WL.

Leukemia. 2012 Feb;26(2):271-9. doi: 10.1038/leu.2011.199. Epub 2011 Aug 16.

37.

Educational paper. The development of new therapies for pediatric oncology.

Horton TM, Berg SL.

Eur J Pediatr. 2011 May;170(5):555-9. doi: 10.1007/s00431-010-1374-5. Epub 2010 Dec 30. Review.

PMID:
21190039
38.

Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.

Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA; ALLNA 2008 Conference.

Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414.

39.

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.

Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL.

Mol Cancer Ther. 2009 Aug;8(8):2232-42. doi: 10.1158/1535-7163.MCT-09-0142. Epub 2009 Aug 11.

40.

Development and validation of a fluorogenic assay to measure separase enzyme activity.

Basu D, Zhang N, Panigrahi AK, Horton TM, Pati D.

Anal Biochem. 2009 Sep 15;392(2):133-8. doi: 10.1016/j.ab.2009.05.046. Epub 2009 Jun 2.

41.

Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM; Children's Oncology Group Study.

J Clin Oncol. 2007 Nov 1;25(31):4922-8.

42.

A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.

Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL; Children's Oncology Group.

Pediatr Blood Cancer. 2008 Apr;50(4):788-92.

43.

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM.

Clin Cancer Res. 2007 Mar 1;13(5):1516-22.

44.

Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines.

Min DJ, Moskowitz NP, Brownstein C, Lee H, Horton TM, Carroll WL.

Apoptosis. 2006 Nov;11(11):1977-86.

PMID:
17013760
45.

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.

Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL.

Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23. Epub 2005 Nov 15.

PMID:
16292537
46.

Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.

Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S.

Clin Cancer Res. 2005 Mar 1;11(5):1884-9.

47.

Outcomes for children with gallbladder abnormalities and sickle cell disease.

Suell MN, Horton TM, Dishop MK, Mahoney DH, Olutoye OO, Mueller BU.

J Pediatr. 2004 Nov;145(5):617-21.

PMID:
15520760
48.

Case series of thrombotic thrombocytopenic purpura in children and adolescents.

Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH.

J Pediatr Hematol Oncol. 2003 Apr;25(4):336-9. Review.

PMID:
12679653
49.

Aseptic meningitis in a child after systemic treatment with high dose cytarabine.

Pease CL, Horton TM, McClain KL, Kaplan SL.

Pediatr Infect Dis J. 2001 Jan;20(1):87-9.

PMID:
11176579
50.

Novel mitochondrial DNA deletion found in a renal cell carcinoma.

Horton TM, Petros JA, Heddi A, Shoffner J, Kaufman AE, Graham SD Jr, Gramlich T, Wallace DC.

Genes Chromosomes Cancer. 1996 Feb;15(2):95-101.

PMID:
8834172

Supplemental Content

Loading ...
Support Center